The use of biochemical markers of bone remodeling in multiple myeloma: A report of the International Myeloma Working Group

Leukemia

Volumn 24, Issue 10, 2010, Pages 1700-1712

  Terpos, E ^a   Dimopoulos, M A ^a   Sezer, O ^b   Roodman, D ^c   Abildgaard, N ^d   Vescio, R ^e   Tosi, P ^f   Garcia Sanz, R ^g   Davies, F ^h   Chanan Khan, A ⁱ   Palumbo, A ^j   Sonneveld, P ^k   Drake, M T ^l   Harousseau, J L ^m   Anderson, K C ⁿ   Durie, B G M ^e  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^h ROYAL MARSDEN HOSPITAL   (United Kingdom)

ⁱ ROSWELL PARK CANCER INSTITUTE   (United States)

^j UNIVERSITY OF TURIN   (Italy)

^k ERASMUS MEDICAL CENTER   (Netherlands)

^l MAYO CLINIC   (United States)

^m INSTITUT DE BIOLOGIE   (France)

ⁿ DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

bone markers; CTX; ICTP; myeloma; NTX

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; MATRIX METALLOPROTEINASE;

BONE ATROPHY; BONE DESTRUCTION; BONE DISEASE; BONE REMODELING; BONE TURNOVER; DISEASE ACTIVITY; DISEASE COURSE; EARLY DIAGNOSIS; HUMAN; MORBIDITY; MULTIPLE MYELOMA; OSSIFICATION; OSTEOLYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW;

EID: 77957991625     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.173     Document Type: Review

References (97)

1. Coleman RE. Bisphosphonates: clinical experience. Oncologist 2004; 9 (Suppl 4): 14-27.
2. Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysio-logy and management. Ann Oncol 2005; 16: 1223-1231.
3. Roodman GD. Pathogenesis of myeloma bone disease. Leukemia 2009; 23: 435-441.
4. Sezer O. Myeloma bone disease: Recent advances in biology, diagnosis and treatment. Oncologist 2009; 14: 276-283.
5. Mileshkin L, Blum R, Seymour JF, Patrikeos A, Hicks RJ, Prince HM. A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma. Eur J Haematol 2004; 72: 32-37.
6. Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia 2009; 23: 1545-1556.
7. Abildgaard N, Brixen K, Eriksen EF, Kristensen JE, Nielsen JL, Heickendorff L. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica 2004; 89: 567-577.
8. Terpos E, Sezer O, Croucher PI, García-Sanz R, Boccadoro M, San Miguel J et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009; 20: 1303-1317.
9. Terpos E, Dimopoulos MA, Sezer O. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 2007; 21: 1875-1884.
10. von Metzler I, Krebbel H, Hecht M, Manz RA, Fleissner C, Mieth M et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007; 21: 2025-2034.
11. Calvo MS, Eyre DR, Gundberg CM. Molecular basis and clinical application of biological markers of bone turnover. Endocrine Rev 1996; 17: 333-368.
12. Hannon RA, Eastell R. Biochemical markers of bone turnover and fracture prediction. J Br Menopause Soc 2003; 9: 10-15.
13. Hannon RA, Clowes JA, Eagleton AC, Al Hadari A, Eastell R, Blumsohn A. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 2004; 34: 187-194.
14. Woitge HW, Pecherstorfer M, Horn E, Keck AV, Diel IJ, Bayer P et al. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br J Cancer 2001; 84: 344-351.
15. Seibel MJ. Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev 2005; 26: 97-122.
16. Delmas PD. Bone marker nomenclature. Bone 2001; 28: 575-576.
17. Prockop DJ, Keiser HR, Sjoerdsma A. Gastrointestinal absorption and renal excretion of hydroxyproline peptides. Lancet 1962; 2: 527-528.
18. Al-Dehaimi AW, Blumsohn A, Eastell R. Serum galactosyl hydroxylysine as a biochemical marker of bone resorption. Clin Chem 1999; 45: 676-681.
19. Leigh SD, Ju HS, Lundgard R, Daniloff GY, Liu V. Development of an immunoassay for urinary galactosylhydroxylysine. J Immunol Methods 1998; 220: 169-178.
20. Eyre DR, Paz MA, Gallop PM. Cross-linking in collagen and elastin. Annu Rev Biochem 1984; 53: 717-748.
21. Knott L, Bailey AJ. Collagen cross-links in mineralizing tissues: a review of their chemistry, function, and clinical relevance. Bone 1998; 22: 181-187.
22. Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003; 18: 859-867.
23. Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992; 7: 1251-1258.
24. Apone S, Lee MY, Eyre DR. Osteoclasts generate cross-linked collagen N-telopeptides (NTx) but not free pyridinolines when cultured on human bone. Bone 1997; 21: 129-136.
25. Bonde M, Garnero P, Fledelius C, Qvist P, Delmas PD, Christiansen C. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J Bone Miner Res 1997; 12: 1028-1034.
26. Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P et al. Serum crosslaps one step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 1998; 44: 2281-2289.
27. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radio-immunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993; 39: 635-640.
28. Sassi ML, Eriksen H, Risteli L, Niemi S, Mansell J, Gowen M et al. Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 2000; 26: 367-373.
29. Janckila AJ, Takahashi K, Sun SZ, Yam LT. Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem 2001; 47: 74-80. (Pubitemid 32064278)
30. Janckila AJ, Neustadt DH, Nakasato YR, Halleen JM, Hentunen T, Yam LT. Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis. Clin Chim Acta 2002; 320: 49-58.
31. Lam WK, Eastlund DT, Li CY, Yam LT. Biochemical properties of tartrate-resistant acid phosphatase in serum of adults and children. Clin Chem 1978; 24: 1105-1108.
32. Ylipahkala H, Halleen JM, Kaija H, Vihko P, Väänänen HK. Tartrate-resistant acid phosphatase 5B circulates in human serum in complex with alpha2-macroglobulin and calcium. Biochem Biophys Res Commun 2003; 308: 320-324.
33. Moss DW. Perspectives in alkaline phosphatase research. Clin Chem 1992; 38: 2486-2492.
34. Gallop PM, Lian JB, Hauschka PV. Carboxylated calcium-binding proteins and vitamin K. N Engl J Med 1980; 302: 1460-1466.
35. Nelsestuen GL, Shah AM, Harvey SB. Vitamin K-dependent proteins. Vitam Horm 2000; 58: 355-389.
36. Young MF, Kerr JM, Ibaraki K, Heegaard AM, Robey PG. Structure, expression, and regulation of the major noncollagenous matrix proteins of bone. Clin Orthop Relat Res 1992; 281: 275-294.
37. Sierra J, Villagra A, Paredes R, Cruzat F, Gutierrez S, Javed A et al. Regulation of the bone-specific osteocalcin gene by p300 requires Runx2/Cbfa1 and the vitamin D3 receptor but not p300 intrinsic histone acetyltransferase activity. Mol Cell Biol 2003; 23: 3339-3351.
38. Koeneman KS, Kao C, Ko SC, Yang L, Wada Y, Kallmes DF et al. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J Urol 2000; 18: 102-110.
39. Christenson RH. Biochemical markers of bone metabolism: an overview. Clin Biochem 1997; 30: 573-593.
40. Smedsrod B, Melkko J, Risteli L, Risteli J. Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J 1990; 271: 345-350.
41. Risteli J, Risteli L. Assays of type I procollagen domains and collagen fragments: problems to be solved and future trends. Scand J Clin Lab Invest Suppl 1997; 227: 105-113.
42. Fohr B, Dunstan CR, Seibel MJ. Clinical review 165: Markers of bone remodeling in metastatic bone disease. J Clin Endocrinol Metab 2003; 88: 5059-5075.
43. Nawawi H, Samson D, Apperley J, Girgis S. Biochemical bone markers in patients with multiple myeloma. Clin Chim Acta 1996; 253: 61-77.
44. Abildgaard N, Bentzen SM, Nielsen JL, Heickendorff L. Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Br J Haematol 1997; 96: 103-110.
45. Withold W, Arning M, Schwarz M, Wolf HH, Schneider W. Monitoring of multiple myeloma patients by simultaneously measuring marker substances of bone resorption and formation. Clin Chim Acta 1998; 269: 21-30.
46. Carlson K, Larsson A, Simonsson B, Turesson I, Westin J, Ljunghall S. Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creati-nine (DPD) and serum ICTP, and an evaluation of the DPD/ osteocalcin and ICTP/osteocalcin ratios. Eur J Haematol 1999; 62: 300-306.
47. Woitge HW, Pecherstorfer M, Li Y, Keck AV, Horn E, Ziegler R et al. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 1999; 14: 792-801.
48. Fonseca R, Trendle MC, Leong T, Kyle RA, Oken MM, Kay NE et al. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br J Haematol 2000; 109: 24-29.
49. Terpos E, Palermos J, Tsionos K, Anargyrou K, Viniou N, Papassavas P et al. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma. Eur J Haematol 2000; 65: 331-336.
50. Woitge HW, Horn E, Keck AV, Auler B, Seibel MJ, Pecherstorfer M. Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis. Clin Chem 2001; 47: 686-693.
51. Corso A, Arcaini L, Mangiacavalli S, Astori C, Orlandi E, Lorenzi A et al. Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients. Haematologica 2001; 86: 394-398.
52. Jakob C, Zavrski I, Heider U, Brux B, Eucker J, Langelotz C et al. Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma. Eur J Haematol 2002; 69: 37-42.
53. Alexandrakis MG, Passam FH, Malliaraki N, Katachanakis C, Kyriakou DS, Margioris AN. Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients. Clin Chim Acta 2002; 325: 51-57.
54. Abildgaard N, Brixen K, Kristensen JE, Eriksen EF, Nielsen JL, Heickendorff L. Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haematol 2003; 120: 235-242.
55. Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003; 102: 1064-1069.
56. Terpos E, de la Fuente J, Szydlo R, Hatjiharissi E, Viniou N, Meletis J et al. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. Int J Cancer 2003; 106: 455-457.
57. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23: 4925-4935.
58. Kuliszkiewicz-Janus M, Ma"ecki R, Zó"taszek A, Zastawny M. The significance of carboxy-terminal telopeptide of type I collagen (ICTP) and osteocalcin (OC) in assessment of bone disease in patients with multiple myeloma. Leuk Lymphoma 2005; 46: 1749-1753.
59. Dizdar O, Barista I, Kalyoncu U, Karadag O, Hascelik G, Cila A et al. Biochemical markers of bone turnover in diagnosis of myeloma bone disease. Am J Hematol 2007; 82: 185-191.
60. Jakob C, Sterz J, Liebisch P, Mieth M, Rademacher J, Goerke A et al. Incorporation of the bone marker carboxy-terminal telopep-tide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma. Leukemia 2008; 22: 1767-1772.
61. Terpos E, Palermos J, Viniou N, Vaiopoulos G, Meletis J, Yataganas X. Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment. Calcif Tissue Int 2001; 68: 285-290.
62. Clark RE, Flory AJ, Ion EM, Woodcock BE, Durham BH, Fraser WD. Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma. Blood 2000; 96: 2697-2702.
63. Terpos E, Politou M, Szydlo R, Nadal E, Avery S, Olavarria E et al. Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. Leukemia 2004; 18: 1420-1426.
64. Abildgaard N, Glerup H, Rungby J, Bendix-Hansen K, Kassem M, Brixen K et al. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol 2000; 64: 121-129.
65. Jakob C, Zavrski I, Heider U, Bollow M, Schulz CO, Fleissner C et al. Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography. Clin Cancer Res 2003; 9: 3047-3051.
66. Alexandrakis MG, Kyriakou DS, Passam FH, Malliaraki N, Vlachonikolis IG, Karkavitsas N et al. Urinary N-telopeptide levels in multiple myeloma patients, correlation with Tc-99m-sestaMIBI scintigraphy and other biochemical markers of disease activity. Hematol Oncol 2003; 21: 17-24.
67. Terpos E, Berenson J, Cook RJ, Lipton A, Coleman RE. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia 2010; 24: 1043-1049.
68. Turesson I, Abildgaard N, Ahlgren T, Dahl I, Holmberg E, Hjorth M et al. Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors. Br J Haematol 1999; 106: 1005-1012.
69. Schütt P, Rebmann V, Brandhorst D, Wiefelspütz J, Ebeling P, Opalka B et al. The clinical significance of soluble human leukocyte antigen class-I, ICTP, and RANKL molecules in multiple myeloma patients. Hum Immunol 2008; 69: 79-87.
70. Terpos E, Berenson J, Lipton A, Coleman R, Cook R. High baseline NTX predicts for inferior survival and shorter time to first SRE in Multiple Myeloma. Clin Lymphoma Myeloma 2009; 9 (Suppl 1): 50-51.
71. Elomaa I, Risteli L, Laakso M, Lahtinen R, Virkkunen P, Risteli J. Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma. Eur J Cancer 1996; 32A: 1166-1170.
72. Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001; 91: 1191-1200.
73. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7: 377-387.
74. Menssen HD, Sakalov A, Fontana A, Herrmann Z, Boewer C, Facon T et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 2002; 20: 2353-2359.
75. Terpos E, Viniou N, de la Fuente J, Meletis J, Voskaridou E, Karkantaris C et al. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-micro-globulin in multiple myeloma. Eur J Haematol 2003; 70: 34-42.
76. Terpos E, Mihou D, Szydlo R, Tsimirika K, Karkantaris C, Politou M et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteo-protegerin ratio. Leukemia 2005; 19: 1969-1976.
77. Lipton A, Cook RJ, Coleman RE, Smith MR, Major P, Terpos E et al. Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. Clin Lymphoma Myeloma 2007; 7: 346-353.
78. Henry D, von Moos R, Vadhan-Raj S, Hungria V, Spencer A, Hirsh V et al. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Eur J Cancer 2009: (Suppl 3): 12 (abstract 20LBA).
79. Seidel C, Hjertner Ø, Abildgaard N, Heickendorff L, Hjorth M, Westin J et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 2001; 98: 2269-2271.
80. Lipton A, Ali SM, Leitzel K, Chinchilli V, Witters L, Engle L et al. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 2002; 8: 2306-2310.
81. Goranova-Marinova V, Goranov S, Pavlov P, Tzvetkova T. Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations. Haemato-logica 2007; 92: 1000-1001.
82. Martini G, Gozzetti A, Gennari L, Avanzati A, Nuti R, Lauria F. The effect of zoledronic acid on serum osteoprotegerin in early stage multiple myeloma. Haematologica 2006; 91: 1720-1721.
83. Terpos E, Kastritis E, Roussou M, Heath D, Christoulas D, Anagnostopoulos N et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008; 22: 2247-2256.
84. Kraj M, Owczarska K, Sokołowska U, Centkowski P, Pogłód R, Kruk B. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients. Arch Immunol Ther Exp 2005; 53: 454-464.
85. Nanci A. Content and distribution of noncollagenous matrix proteins in bone and cementum: relationship to speed of formation and collagen packing density. J Struct Biol 1999; 126: 256-269.
86. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483-2494.
87. Politou MC, Heath DJ, Rahemtulla A, Szydlo R, Anagnostopoulos A, Dimopoulos MA et al. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer 2006; 119: 1728-1731.
88. Kaiser M, Mieth M, Liebisch P, Oberländer R, Rademacher J, Jakob C et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Hematol 2008; 80: 490-494.
89. Haaber J, Abildgaard N, Knudsen LM, Dahl IM, Lodahl M, Thomassen M et al. Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis. Br J Haematol 2008; 140: 25-35.
90. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy Jr JD et al. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007; 109: 2106-2111.
91. Tosi P, Zamagni E, Cellini C, Parente R, Cangini D, Tacchetti T et al. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. Eur J Haematol 2006; 76: 399-404.
92. Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Mitsiades C et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008; 22: 1925-1932.
93. Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005; 131: 71-73. (Pubitemid 43899710)
94. Zangari M, Yaccoby S, Cavallo F, Esseltine D, Tricot G. Response to bortezomib and activation of osteoblasts in multiple myeloma. Clin Lymphoma Myeloma 2006; 7: 109-114. (Pubitemid 44596593)
95. Heider U, Kaiser M, Müller C, Jakob C, Zavrski I, Schulz CO et al. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 2006; 77: 233-238.
96. Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Bonomini S, Crugnola M et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007; 110: 334-338.
97. Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand co ncentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006; 135: 688-692.